Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T16:57:52.425Z.
Calculation as of: 2026-10-06T16:57:52.425Z.
Quote observation: 2026-10-06T16:55:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 789431897149b7eb66dfe5c794b774a541b173055368acfdd0e045abcb2ddd87
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$260.96M
Free Cash Flow Yield
N/A
TTM Avg
21.58%
3Y Avg
20.83%
5Y Avg
20.83%
Market Cap
$259.85M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.45M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.39M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.09M
Free Cash Flow Yield
0.22%
TTM Avg
0.70%
3Y Avg
0.62%
5Y Avg
0.64%
Market Cap
$264.83M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.41M
Free Cash Flow Yield
N/A
TTM Avg
26.18%
3Y Avg
21.57%
5Y Avg
18.84%
Market Cap
$267.03M
Free Cash Flow Yield
N/A
TTM Avg
2.40%
3Y Avg
2.40%
5Y Avg
2.40%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palisade Bio, Inc. (PALI) | $261.24M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $260.96M | N/A | 21.58% | 20.83% | 20.83% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $259.85M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $262.45M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $265.39M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.09M | 0.22% | 0.70% | 0.62% | 0.64% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.83M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $265.41M | N/A | 26.18% | 21.57% | 18.84% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.03M | N/A | 2.40% | 2.40% | 2.40% |
| Scribe Therapeutics Inc. (SCTX)vs › | $269.11M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
